Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...

AbbVie (ABBV) rebounds after losses, gaining ~% as analysts stay bullish. Discover why its obesity drug deal boosts long-term ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.